Work for Sophiris Bio Inc.?
Claim Your Profile
Please check back to see if Sophiris Bio Inc. has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Sophiris Bio Inc. is a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). Topsalysin is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations in the transition zone of the prostate and in and around prostate tumor cells.
